Online inquiry

IVTScrip™ mRNA-Anti-CD19, SGN-19A(Cap 0, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ14736MR)

This product GTTS-WQ14736MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD19 gene. The antibody can be applied in B cell acute lymphoblastic leukemia (B cell ALL), Refractory B-lineage non-Hodgkin lymphoma research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001178098.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 930
UniProt ID P15391
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD19, SGN-19A(Cap 0, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ14736MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ14757MR IVTScrip™ mRNA-Anti-TNFRSF8, SGN-35(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA SGN-35
GTTS-WQ1627MR IVTScrip™ mRNA-Anti-F10&F9, ACE-910(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ACE-910
GTTS-WQ604MR IVTScrip™ mRNA-Anti-RTN4, 6A3-IgG4(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA 6A3-IgG4
GTTS-WQ4956MR IVTScrip™ mRNA-Anti-GP, c2G4-N(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA c2G4-N
GTTS-WQ6745MR IVTScrip™ mRNA-Anti-EGFR, DS 992(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA DS 992
GTTS-WQ8035MR IVTScrip™ mRNA-Anti-F, H1H3592P3(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA H1H3592P3
GTTS-WQ12159MR IVTScrip™ mRNA-Anti-MSLN, MORAb-009(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA MORAb-009
GTTS-WQ14402MR IVTScrip™ mRNA-Anti-IFNA1, RhuMAB IFNalpha(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA RhuMAB IFNalpha
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW